Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® and $23.9 million for EMPAVELI® SYFOVRE showed continued strong demand with growth.
IVERIC bio, Inc. (NASDAQ:NASDAQ:ISEE) Q3 2022 Earnings Conference Call November 03, 2022, 08:00 ET Company Participants Kathy Galante - SVP, IR & Corporate Communications Glenn.